Syllabus database for doctoral courses
-
Startpage
Syllabus database for doctoral courses
SYLLABI FOR DOCTORAL COURSES
| Swedish title | Cirkulerande tumörceller |
|---|---|
| English title | Circulating tumor cells |
| Course number | 2663 |
| Credits | 1.5 |
| Responsible KI department | Institutionen för mikrobiologi, tumör- och cellbiologi |
| Specific entry requirements | |
| Grading | Passed /Not passed |
| Established by | The Board of Doctoral Education |
| Established | 2014-09-08 |
| Purpose of the course | |
| Intended learning outcomes | After attending the course the student will be able to explain how a circulating tumor cells (CTC) is defined, will be able to reflect on and discuss professionally what the clinical needs are for CTC capture and analyses, the relative role of metastases in morbidity and mortality in at least one type of cancer, have an overview of what is known of CTC biology, including the contribution of epithelial mesenchymal transition (EMT), blood flow, the seed and soil hypothesis, what scientific knowledge is missing and how some of that knowledge can be extended, be able to reflect on the potential benefits of CTC enumeration and pathogenic mechanism-based analyses in clinical management of at least one type of cancer, be able to reflect on the ultimate benefits of a comprehensive CTC capture and analysis on cancer patient management. |
| Contents of the course | Recommended literature: Circulating tumor cells (CTCs) are cells that have detached from a primary tumor and circulate in the bloodstream. CTCs may constitute seeds for subsequent growth of additional tumors (metastasis) in different tissues. Some of the outstanding scientific issues are: how does a CTC end up in the circulation? Does that require active migration? Is migration targeted or random? Does migration require an epithelial cell to become partially mesenchymal? How does that relate to EMT? What additional properties are altered as part of any EMT? Acquirement of stem cell properties? If so, how is that selected for? What is the relation, if any, between stem cell properties and ability to become a tumor initiating cell? What is the half-life of CTC? How can they exist at all? How do they remain suspended? How do they attach, if they do? By receptor-ligand binding or by size? What role does the path of the blood flow play? What role does the seed and soil hypothesis play? How do they know to invade? What role does directionality, and random migration respectively, play? What is the mechanisms of dormancy? Awakening from dormancy? In what aspects of clinical management may CTC enumeration and analyses be of use? What are the actual clinical diagnostic needs for several forms of cancer? How important, if at all, is metastases in several forms of cancer? What types of analyses of CTCs are possible today? What specific analyses would we like to be able to perform, to analyse the actual pathogenic process? What would the impact be if that were possible? |
| Teaching and learning activities | Orientation, selfdirected studies of the scientific literature, reflection, demonstrations of instrumentation, evaluation of prepared research results, authoring a review article and a research plan, group discussions, interactive seminars with clinicians, clinical laboratory physicians and with scientists, summary discussion, feedback. |
| Compulsory elements | Physical presence daily, for 5 days, 9 a.m. to 5 p.m., is mandatory in order to achieve the desired face-to-face communication and colaboration. One days absence can be compensated by authoring one additional research plan. |
| Examination | The doctoral student shall contribute to, jointly, with the other students, authoring an in principle publishable review article on the current challenges in the field of Circulating Tumor Cells. The contribution of each individual shall be clearly identifiable. Each doctoral student shall also submit an individual written (maximum 5 page typewritten) in principle viable research plan to address at least one of the current issues in CTC research as identified in the background/review section. |
| Literature and other teaching material | Alix-Panabieres, C., and Pantel, K. (2014). Technologies for detection of circulating tumor cells: facts and vision. Lab on a chip 14, 57-62. Ashworth, T.R. (1869). A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Australian Medical Journal, 146 -147. Banys, M., Neubauer, H., Ruckhaeberle, E., and Fehm, T. (2014). Expression of Stem Cell and Epithelial-Mesenchymal Transition Markers in Circulating Tumor Cells of Breast Cancer Patients. BioMed research international. Butler, T.P., and Gullino, P.M. (1975). Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer research 35, 512-516. Coumans, F.A., Siesling, S., and Terstappen, L.W. (2013). Detection of cancer before distant metastasis. BMC cancer 13, 283. Fidler, I.J. (1970). Metastasis: guantitative analysis of distribution and fate of tumor embolilabeled with 125 I-5-iodo-2'-deoxyuridine. Journal of the National Cancer Institute 45, 773-782. Fidler, I.J. (1973). The relationship of embolic homogeneity, number, size and viability to the incidence of experimental metastasis. European journal of cancer 9, 223-227. Friberg, S., and Mattson, S. (1997). On the growth rates of human malignant tumors: implications for medical decision making. J Surg Oncol 65, 284-297. Husemann, Y., Geigl, J.B., Schubert, F., Musiani, P., Meyer, M., Burghart, E., Forni, G., Eils, R., Fehm, T., Riethmuller, G., et al. (2008). Systemic spread is an early step in breast cancer. Cancer cell 13, 58-68. Jin, C., McFaul, S.M., Duffy, S.P., Deng, X., Tavassoli, P., Black, P.C., and Ma, H. (2014). Technologies for label-free separation of circulating tumor cells: from historical foundations to recent developments. Lab on a chip 14, 32-44. Klevebring, D., Rosin, G., Ma, R., Lindberg, J., Czene, K., Kere, J., Fredriksson, I., Bergh, J., and Hartman, J. (2014). Sequencing of breast cancer stem cell populations indicates a dynamic conversion between differentiation states in vivo. Breast cancer research : BCR 16, R72. Martelotto, L., Ng, C., Piscuoglio, S., Weigelt, B., and Reis-Filho, J. (2014). Breast cancer intra-tumor heterogeneity. Breast Cancer Research 16, 210. Wong, I.Y., Javaid, S., Wong, E.A., Perk, S., Haber, D.A., Toner, M., and Irimia, D. (2014). Collective and individual migration following the epithelial-mesenchymal transition. Nature materials. Yu, M., Bardia, A., Aceto, N., Bersani, F., Madden, M.W., Donaldson, M.C., Desai, R., Zhu, H., Comaills, V., Zheng, Z., et al. (2014). Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 345, 216-220. |
Course responsible |
Christer Ericsson Institutionen för mikrobiologi, tumör- och cellbiologi 0739596686 Christer.Ericsson@ki.se Nobels väg 16 171 77 Stockholm |
| Contact person |
